Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Cortés J[au]:

Search results

Items: 1 to 50 of 2138

1.

Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.

Pivot X, Pegram M, Cortes J, Lüftner D, Lyman GH, Curigliano G, Bondarenko I, Yoon YC, Kim Y, Kim C.

Eur J Cancer. 2019 Aug 21;120:1-9. doi: 10.1016/j.ejca.2019.07.015. [Epub ahead of print]

PMID:
31445454
2.

The rise of oncology biosimilars: from process to promise.

Verrill M, Declerck P, Loibl S, Lee J, Cortes J.

Future Oncol. 2019 Aug 23. doi: 10.2217/fon-2019-0145. [Epub ahead of print]

PMID:
31441323
3.

POSEIDON phase 1b results: safety, efficacy and ctDNA response of taselisib combined with tamoxifen in hormone receptor positive metastatic breast cancer patients.

Baird RD, van Rossum AG, Oliveira M, Beelen KJ, Gao M, Schrier M, Mandjes IA, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, Van Tinteren H, Callari M, Beddowes E, Pérez-Garcia J, Rosing H, Platte E, Nederlof PM, Schot M, de Vries Schultink AH, Bernards R, Saura C, Gallagher WM, Cortés J, Caldas C, Linn SC.

Clin Cancer Res. 2019 Aug 22. pii: clincanres.0508.2019. doi: 10.1158/1078-0432.CCR-19-0508. [Epub ahead of print]

PMID:
31439579
4.

Trends of maxillofacial trauma: An update from the prospective register of a multicenter study in emergency services of Chile.

Werlinger F, Villalón M, Duarte V, Acevedo R, Aguilera R, Alcocer D, Badillo O, Briones R, Condal C, Del Río M, García R, Herrera M, Jaramillo J, Merchan F, Nasi M, Osbén R, Rivera A, Riviello S, Rojas P, Vidal C, Rodríguez G, Schild S, Arroyo E, Alvarado MJ, Sepúlveda P, Cortés J.

Med Oral Patol Oral Cir Bucal. 2019 Aug 19. pii: 22985. doi: 10.4317/medoral.22985. [Epub ahead of print]

5.

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragan E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Ráčil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C.

J Clin Oncol. 2019 Aug 20:JCO1900416. doi: 10.1200/JCO.19.00416. [Epub ahead of print]

PMID:
31430225
6.

Prematurity and ADHD in Childhood: An Observational Register-Based Study in Catalonia.

Perapoch J, Vidal R, Gómez-Lumbreras A, Hermosilla E, Riera L, Cortés J, Céspedes MC, Ramos-Quiroga JA, Morros R.

J Atten Disord. 2019 Aug 14:1087054719864631. doi: 10.1177/1087054719864631. [Epub ahead of print]

PMID:
31409171
7.

Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study.

Cortes J, Huynh L, Mendelson E, Brandt P, Dalal D, DerSarkissian M, Cortina D, Narkhede S, Sheng Duh M.

Leuk Lymphoma. 2019 Aug 13:1-10. doi: 10.1080/10428194.2019.1644332. [Epub ahead of print]

PMID:
31409168
8.

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM.

Lancet Haematol. 2019 Aug 7. pii: S2352-3026(19)30114-0. doi: 10.1016/S2352-3026(19)30114-0. [Epub ahead of print]

PMID:
31400961
9.

Mist1 Expression Is Required for Paneth Cell Maturation.

Dekaney CM, King S, Sheahan B, Cortes J.

Cell Mol Gastroenterol Hepatol. 2019 Jul 19. pii: S2352-345X(19)30090-6. doi: 10.1016/j.jcmgh.2019.07.003. [Epub ahead of print]

10.

Approach to ocular toxoplasmosis including pregnant women.

Cortés JA, Roncancio Á, Uribe LG, Cortés-Luna CF, Montoya JG.

Curr Opin Infect Dis. 2019 Jul 15. doi: 10.1097/QCO.0000000000000577. [Epub ahead of print]

PMID:
31313714
11.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F.

Cancer. 2019 Jul 16. doi: 10.1002/cncr.32387. [Epub ahead of print]

PMID:
31310323
12.

Genetics of Thyroid Disorders.

Cortés JMR, Zerón HM.

Folia Med (Plovdiv). 2019 Jun 1;61(2):172-179. doi: 10.2478/folmed-2018-0078. Review.

PMID:
31301652
13.

Catalyst Behavior in Metal-Catalyzed Carbonyl-Olefin Metathesis.

Hanson CS, Psaltakis MC, Cortes JJ, Devery JJ 3rd.

J Am Chem Soc. 2019 Jul 31;141(30):11870-11880. doi: 10.1021/jacs.9b02613. Epub 2019 Jul 22.

PMID:
31276383
14.

Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia.

Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S.

Am J Hematol. 2019 Jul 4. doi: 10.1002/ajh.25571. [Epub ahead of print] No abstract available.

PMID:
31273842
15.

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.

Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M.

Leuk Lymphoma. 2019 Jun 27:1-4. doi: 10.1080/10428194.2019.1633635. [Epub ahead of print] No abstract available.

PMID:
31246142
16.

Phylogeography and Population Genetics of Vicugna vicugna: Evolution in the Arid Andean High Plateau.

González BA, Vásquez JP, Gómez-Uchida D, Cortés J, Rivera R, Aravena N, Chero AM, Agapito AM, Varas V, Wheleer JC, Orozco-terWengel P, Marín JC.

Front Genet. 2019 Jun 6;10:445. doi: 10.3389/fgene.2019.00445. eCollection 2019.

17.

PTEN Activity Defines an Axis for Plasticity at Cortico-Amygdala Synapses and Influences Social Behavior.

Sánchez-Puelles C, Calleja-Felipe M, Ouro A, Bougamra G, Arroyo A, Diez I, Erramuzpe A, Cortés J, Martínez-Hernández J, Luján R, Navarrete M, Venero C, Chan A, Morales M, Esteban JA, Knafo S.

Cereb Cortex. 2019 Jun 26. pii: bhz103. doi: 10.1093/cercor/bhz103. [Epub ahead of print]

PMID:
31240311
18.

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F.

Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25553. [Epub ahead of print]

PMID:
31237017
19.

Extra-skeletal manifestations in mice affected by Clcn7-dependent autosomal dominant osteopetrosis type 2 clinical and therapeutic implications.

Maurizi A, Capulli M, Curle A, Patel R, Ucci A, Côrtes JA, Oxford H, Lamandé SR, Bateman JF, Rucci N, Teti A.

Bone Res. 2019 Jun 11;7:17. doi: 10.1038/s41413-019-0055-x. eCollection 2019.

20.

Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.

Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):509-515.e1. doi: 10.1016/j.clml.2019.05.008. Epub 2019 May 13.

21.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17. Review.

PMID:
31209280
22.

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Shih YT, Cortes JE, Kantarjian HM.

Lancet Haematol. 2019 Aug;6(8):e398-e408. doi: 10.1016/S2352-3026(19)30087-0. Epub 2019 Jun 14.

PMID:
31208943
23.

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.

Gavilá J, De La Haba J, Bermejo B, Rodríguez-Lescure Á, Antón A, Ciruelos E, Brunet J, Muñoz-Couselo E, Santisteban M, Rodríguez Sánchez CA, Santaballa A, Sánchez Rovira P, García Sáenz JÁ, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanchís A, Lao Romera J, Aguirre E, Cortés J, Llombart-Cussac A.

Clin Transl Oncol. 2019 Jun 15. doi: 10.1007/s12094-019-02145-4. [Epub ahead of print]

PMID:
31203575
24.

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ.

Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31175001
25.

Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: A study in three European data sources.

Forns J, Cainzos-Achirica M, Hellfritzsch M, Morros R, Poblador-Plou B, Hallas J, Giner-Soriano M, Prados-Torres A, Pottegård A, Cortés J, Castellsagué J, Jacquot E, Deltour N, Perez-Gutthann S, Pladevall M.

Pharmacoepidemiol Drug Saf. 2019 Jul;28(7):965-975. doi: 10.1002/pds.4803. Epub 2019 Jun 6.

26.

Differential Poststroke Motor Recovery in an Arm Versus Hand Muscle in the Absence of Motor Evoked Potentials.

Schambra HM, Xu J, Branscheidt M, Lindquist M, Uddin J, Steiner L, Hertler B, Kim N, Berard J, Harran MD, Cortes JC, Kitago T, Luft A, Krakauer JW, Celnik PA.

Neurorehabil Neural Repair. 2019 Jul;33(7):568-580. doi: 10.1177/1545968319850138. Epub 2019 Jun 6.

PMID:
31170880
27.

Adherence to reporting guidelines increases the number of citations: the argument for including a methodologist in the editorial process and peer-review.

Vilaró M, Cortés J, Selva-O'Callaghan A, Urrutia A, Ribera JM, Cardellach F, Basagaña X, Elmore M, Vilardell M, Altman D, González JA, Cobo E.

BMC Med Res Methodol. 2019 May 31;19(1):112. doi: 10.1186/s12874-019-0746-4.

28.

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.

Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M.

Cancer. 2019 May 31. doi: 10.1002/cncr.32196. [Epub ahead of print]

PMID:
31150121
29.

Transfer to the Local Stroke Center versus Direct Transfer to Endovascular Center of Acute Stroke Patients with Suspected Large Vessel Occlusion in the Catalan Territory (RACECAT): Study protocol of a cluster randomized within a cohort trial.

Abilleira S, Pérez de la Ossa N, Jiménez X, Cardona P, Cocho D, Purroy F, Serena J, Román LS, Urra X, Vilaró M, Cortés J, González JA, Chamorro Á, Gallofré M, Jovin T, Molina C, Cobo E, Dávalos A, Ribó M.

Int J Stroke. 2019 May 29:1747493019852176. doi: 10.1177/1747493019852176. [Epub ahead of print]

PMID:
31142219
30.

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.

De Mattos-Arruda L, Sammut SJ, Ross EM, Bashford-Rogers R, Greenstein E, Markus H, Morganella S, Teng Y, Maruvka Y, Pereira B, Rueda OM, Chin SF, Contente-Cuomo T, Mayor R, Arias A, Ali HR, Cope W, Tiezzi D, Dariush A, Dias Amarante T, Reshef D, Ciriaco N, Martinez-Saez E, Peg V, Ramon Y Cajal S, Cortes J, Vassiliou G, Getz G, Nik-Zainal S, Murtaza M, Friedman N, Markowetz F, Seoane J, Caldas C.

Cell Rep. 2019 May 28;27(9):2690-2708.e10. doi: 10.1016/j.celrep.2019.04.098.

31.

Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases.

Murueta-Goyena A, Del Pino R, Reyero P, Galdós M, Arana B, Lucas-Jiménez O, Acera M, Tijero B, Ibarretxe-Bilbao N, Ojeda N, Peña J, Cortés J, Gómez-Esteban JC, Gabilondo I.

Mov Disord. 2019 May 28. doi: 10.1002/mds.27728. [Epub ahead of print]

PMID:
31136022
32.

Hedgehog signaling inhibitors in solid and hematological cancers.

Cortes JE, Gutzmer R, Kieran MW, Solomon JA.

Cancer Treat Rev. 2019 Jun;76:41-50. doi: 10.1016/j.ctrv.2019.04.005. Epub 2019 May 6. Review.

33.

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.

Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H.

Leuk Lymphoma. 2019 May 24:1-9. doi: 10.1080/10428194.2019.1617862. [Epub ahead of print]

PMID:
31125272
34.

Improving attribution of adverse events in oncology clinical trials.

George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS.

Cancer Treat Rev. 2019 Jun;76:33-40. doi: 10.1016/j.ctrv.2019.04.004. Epub 2019 Apr 25. Review.

PMID:
31108240
35.

The safety of eribulin for the treatment of metastatic breast cancer.

Perez-Garcia JM, Cortes J.

Expert Opin Drug Saf. 2019 May;18(5):347-355. doi: 10.1080/14740338.2019.1608946. Epub 2019 May 20. Review.

PMID:
31107111
36.

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.

Pascual T, Martin M, Fernández-Martínez A, Paré L, Alba E, Rodríguez-Lescure Á, Perrone G, Cortés J, Morales S, Lluch A, Urruticoechea A, González-Farré B, Galván P, Jares P, Rodriguez A, Chic N, Righi D, Cejalvo JM, Tonini G, Adamo B, Vidal M, Villagrasa P, Muñoz M, Prat A.

Front Oncol. 2019 Apr 26;9:303. doi: 10.3389/fonc.2019.00303. eCollection 2019.

37.

Prediction of Alzheimer's disease dementia with MRI beyond the short-term: Implications for the design of predictive models.

Moscoso A, Silva-Rodríguez J, Aldrey JM, Cortés J, Fernández-Ferreiro A, Gómez-Lado N, Ruibal Á, Aguiar P; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2019 Apr 30;23:101837. doi: 10.1016/j.nicl.2019.101837. [Epub ahead of print]

38.

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients.

Cuyàs E, Fernández-Arroyo S, Buxó M, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Verdura S, Brunet J, López-Bonet E, Garcia M, Saidani S, Joven J, Martin-Castillo B, Menendez JA.

Aging (Albany NY). 2019 May 9;11(9):2874-2888. doi: 10.18632/aging.101960.

39.

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J.

Future Oncol. 2019 Jul;15(19):2211-2225. doi: 10.2217/fon-2019-0180. Epub 2019 May 10.

40.

[Laparoscopic renal cyst excision: Large simple renal cyst treatment with renal cell carcinoma cells in its wall. Histogenetic considerations and bibliographic review.]

Serrano Á, Sánchez M, Ciappara M, López E, Laso S, Jerez T, Barrera J, Cortés JA, González-Peramato P, Blazquez J, Moreno J.

Arch Esp Urol. 2019 May;72(4):422-428. Review. Spanish.

PMID:
31070139
41.

Fluidal pyroclasts reveal the intensity of peralkaline rhyolite pumice cone eruptions.

Clarke B, Calder ES, Dessalegn F, Fontijn K, Cortés JA, Naylor M, Butler I, Hutchison W, Yirgu G.

Nat Commun. 2019 May 1;10(1):2010. doi: 10.1038/s41467-019-09947-8.

42.

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.

Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF.

J Natl Cancer Inst. 2019 Apr 30. pii: djz042. doi: 10.1093/jnci/djz042. [Epub ahead of print]

PMID:
31037288
43.

Carbohydrate Self-Assembly at Surfaces: STM Imaging of Sucrose Conformation and Ordering on Cu(100).

Abb S, Tarrat N, Cortés J, Andriyevsky B, Harnau L, Schön JC, Rauschenbach S, Kern K.

Angew Chem Int Ed Engl. 2019 Jun 17;58(25):8336-8340. doi: 10.1002/anie.201901340. Epub 2019 May 24.

PMID:
31018027
44.

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brümmendorf TH; BFORE Study Investigators.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1589-1599. doi: 10.1007/s00432-019-02894-3. Epub 2019 Apr 15.

PMID:
30989330
45.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM.

Cancer. 2019 Aug 1;125(15):2579-2586. doi: 10.1002/cncr.32139. Epub 2019 Apr 15.

PMID:
30985931
46.

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.

Cuyàs E, Buxó M, Ferri Iglesias MJ, Verdura S, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Joven J, Brunet J, López-Bonet E, Garcia M, Saidani S, Queralt Moles X, Martin-Castillo B, Menendez JA.

Front Oncol. 2019 Mar 28;9:193. doi: 10.3389/fonc.2019.00193. eCollection 2019.

47.

IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.

Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM, Easton V, Pollex E, Deurloo R, Dent R.

Future Oncol. 2019 Jun;15(17):1951-1961. doi: 10.2217/fon-2019-0059. Epub 2019 Apr 12.

PMID:
30977385
48.

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.

Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F.

Am J Hematol. 2019 Jul;94(7):E188-E190. doi: 10.1002/ajh.25490. Epub 2019 Apr 29. No abstract available.

PMID:
30977182
49.

Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia.

Cortes JE, Muresan B, Mamolo C, Cappelleri JC, Crescenzo RJ, Su Y, Gambacorti-Passerini C, Heeg B, Douglas Smith B.

Curr Med Res Opin. 2019 Apr 9:1-8. doi: 10.1080/03007995.2019.1605239. [Epub ahead of print]

PMID:
30964361
50.

The antifungal activity and mechanisms of action of quantified extracts from berries, leaves and roots of Phytolacca tetramera.

Butassi E, Svetaz LA, Zhou S, Wolfender JL, Cortés JCG, Ribas JC, Díaz C, Palacio JP, Vicente F, Zacchino SA.

Phytomedicine. 2019 Mar 16:152884. doi: 10.1016/j.phymed.2019.152884. [Epub ahead of print]

PMID:
30922815

Supplemental Content

Loading ...
Support Center